Performance measure of urinary antigen in patients with Streptococcus pneumoniae bacteremia

Selickman, John; Paxos, Mihail; File, Thomas M.; Seltzer, Ryan; Bonilla, Hector

doi:10.1016/j.diagmicrobio.2010.01.005

Cited by 19 publications

(14 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, since macrolide therapy may be associated with improved outcomes independent of any antimicrobial affect [18], the advantages of urinary antigen testing for S. pneumoniae may be even less than the authors proposed [19]. In another retrospective review, when it was compared to the gold standard of blood culture, similar sensitivity was noted [20].…”

Section: Diagnosis Of Capmentioning

confidence: 65%

Management of community-acquired pneumonia

Ehsan¹,

Metersky

2013

Curr Respir Care Rep

View full text Add to dashboard Cite

This article summarizes recent literature related to community-acquired pneumonia (CAP), which continues to represent one of the most common causes of morbidity and mortality throughout the world, especially in the elderly. The impact is even more striking if we take healthcare costs into account. Patients with CAP usually have other comorbidities which not only increase mortality in this group but also add further to its economic burden. Patients with COPD, preexisting cardiac disease, and diabetes are particularly at higher risk for developing more severe pneumonia. New diagnostic modalities, including ultrasonography, are being used more commonly in clinical practice. Procalcitonin levels can be used to identify bacterial pneumonia and to de-escalate antibiotic therapy, resulting in fewer days on antibiotics. Other biomarkers have been used in studies to stratify patients by risk. Guideline-concordant regimens including atypical coverage, and macrolides in particular, appear to provide benefit. More recent data suggest the need for careful screening of patients for cardiovascular risk factors prior to initiating macrolides and fluoroquinolones.

show abstract

Section: Diagnosis Of Capmentioning

confidence: 65%

Management of community-acquired pneumonia

Ehsan¹,

Metersky

2013

Curr Respir Care Rep

View full text Add to dashboard Cite

show abstract

“…The diagnostic yield for ICT in non-SIRS patients was only 1.9%. 14,15 In our study, only 173 (1.5%) blood samples were collected, and none of them was diagnosed as pneumococcal, so the qualified sputum culture was regarded as the gold-standard. Two meta-analysis studies reported the sensitivity was about 75% and specificity was higher than 95%.…”

Section: Clinical Characteristics Associated With Likelihood Of Posmentioning

confidence: 90%

Evaluating the utility of Binax NOW Streptococcus pneumoniae urinary antigen test in adults with community acquired pneumonia in China

Zhou

et al. 2016

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

“…Urinary pathogen nonmolecular FDA-cleared diagnostic assays for S pneumonia and Legionella are an exception, because their results are rapidly available. 10,11 With single-pathogen molecular tests, each test requires the suspicion of a particular pathogen, but with the development of multiple-pathogen molecular assays, particularly for viruses, the tools to advance pathogen-directed therapy may now exist. 12 This article focuses on recently developed molecular multiplex diagnostic assays and platforms, many of which are FDA-cleared, and how their use can enhance and improve the management of CAP.…”

Section: The Diagnostic Problemmentioning

confidence: 99%

What Is the Role of Newer Molecular Tests in the Management of CAP?

Gaydos

2013

Infectious Disease Clinics of North America

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) accounts for major morbidity and mortality in the United States. With improved broad-spectrum antibiotics, the implementation of diagnostic studies has declined and most patients do not have an etiologic pathogen of CAP identified. To enhance the appropriate use of antiviral agents and prevent overuse of antibiotics, the successful management of CAP requires rapid and accurate diagnosis of the etiologic agent of CAP. This article provides an overview of the new rapid molecular tests for the diagnosis of influenza, other respiratory viruses, and bacteria compared with nonmolecular tests and how their use for directed therapy can enhance and improve the management of CAP.

show abstract

Performance measure of urinary antigen in patients with Streptococcus pneumoniae bacteremia

Cited by 19 publications

References 30 publications

Management of community-acquired pneumonia

Management of community-acquired pneumonia

Evaluating the utility of Binax NOW Streptococcus pneumoniae urinary antigen test in adults with community acquired pneumonia in China

What Is the Role of Newer Molecular Tests in the Management of CAP?

Contact Info

Product

Resources

About